{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052053","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.910765+00:00","generated_at":"2026-06-02T23:44:16.702322+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cerus Q1 product revenue up 24% to $38.4M; net loss narrows to $9.7M; ReCePI trial met endpoint","bullets":["Q1 product revenue $38.4M (+24% YoY); total revenue $43.4M (+13%).","Net loss $9.7M ($0.05 EPS) vs $15.6M ($0.09) in Q1 2023; adjusted EBITDA -$2.7M.","ReCePI Phase 3 trial for INTERCEPT Red Blood Cells met primary endpoint in cardiovascular surgery.","FDA approved 12-month shelf life for INTERCEPT Platelet Processing Sets.","FY2024 product revenue guidance reaffirmed at $172-175M; IFC guidance $8-10M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052053","json":"https://secwatch.observer/filing/0000950170-24-052053.json","markdown":"https://secwatch.observer/filing/0000950170-24-052053.md","text":"https://secwatch.observer/filing/0000950170-24-052053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024052053/0000950170-24-052053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024052053/cers-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:44:16.702322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98ceaded38b5e5d4b2c046211c7621d5b895b3a2","claim":"CERUS CORP updated its first quarter ended March 31, 2024 guidance (reaffirmed).","evidence_excerpt":"On May 2, 2024, Cerus Corporation (the “Company”) announced its financial results for its first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024052053/0000950170-24-052053-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}